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Reactivation of the BK polyomavirus is known to lead to severe complications in
kidney transplant patients. The current treatment strategy relies on decreasing the
immunosuppression to allow the immune system to clear the virus. Recently, we
demonstrated a clear association between the resolution of BKV reactivation and
reconstitution of BKV-specific CD4+ T-cells. However, which factors determine the
duration of viral infection clearance remains so far unclear. Here we apply a combination
of in-depth multi-parametric flow cytometry and NGS-based CDR3 beta chain receptor
repertoire analysis of BKV-specific T-cells to a cohort of 7 kidney transplant patients
during the clinical course of BKV reactivation. This way we followed TCR repertoires at
single clone levels and functional activity of BKV-specific T-cells during the resolution of
BKV infection. The duration of BKV clearance did not depend on the number of peripheral
blood BKV-specific T-cells nor on a few immunodominant BKV-specific T-cell clones.
Rather, the T-cell receptor repertoire diversity and exhaustion status of BKV-specific
T-cells affected the duration of viral clearance: high clonotype diversity and lack of
PD1 and TIM3 exhaustion markers on BKV-specific T-cells was associated with short
clearance time. Our data thus demonstrate how the diversity and the exhaustion state
of the T-cells can determine the clinical course of BKV infection.
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INTRODUCTION
Immunosuppression is one of the most important factors contributing to reactivation of the
latent BK polyomavirus (BKV) (1). In fact, BKV reactivation can be observed in up to 80% of all
kidney-transplant recipients (2). In as many as 10% of the cases, patients develop BKV-associated
nephropathy (BKVAN) which can lead to graft loss (2). Currently, there is no antiviral treatment
for BK virus available and the recommended approach to management of BKVAN is a reduction
or modification of immunosuppression, in order to achieve sufficient antiviral control by cellular
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immunity (1, 3). In fact, we and others previously demonstrated
a strong decrease of the BKV load upon reconstitution of BKV-
specific T-cells in renal transplant patients (4, 5). Very recently,
we demonstrated an improved strategy for monitoring of BKV-
specific T-cells by multi-parameter flow cytometry and provided
in-depth characteristics of BKV-specific T-cells associated with
the initiation of BKV load decline (6).
Although the essential role of BKV-specific T-cells for the
initiation of BKV load decline has been well-documented, it
is so far not clear, which factors determine the clinical course
of the disease. The time it takes to clear BKV differs between
patients, and the clearance time after severe BKV infection (BKV
load more than 100,000 copies/ml) can span weeks to even
years (7, 8). On the other hand, sustained BKV infection can
cause immunopathogenesis and lead to irreversible renal graft
tissue damage and graft failure (1). Therefore, understanding
the factors that determine the clearance time once BKV load
starts declining is crucial for understanding the pathogenesis
of BKV-associated nephropathy and for improving therapeutic
management in patients with BKV reactivation.
Besides the magnitude and functional activity of antigen-
specific T-cells, the heterogeneity of clonal repertoire of antigen-
specific T-cells has been suggested to play an important role
in the immune defense. Pathogen recognition by T-cells is
established through the T-cell receptor (TCR) specific for a
cognate epitope in context of the HLA-molecule (9). T-cells with
the same progenitor bear identical TCRs and constitute a T-
cell clone. Recent studies suggest that diversity and size of the
antigen-specific TCR repertoire are two critical determinants for
the successful control of chronic infections and the decreased
repertoire diversity correlates with the decline of immune
responsiveness in aging (10). Although a young adult human
might harbor more than 100 million different TCRs (11), only
a small fraction is specific for a given pathogen (12). Despite the
low frequency, the identification and tracking of antigen specific
TCRs are emerging as valuable tools in the analysis of organ
rejection and control of persistent infections (13–15).
In the present work we provide a further characterization of
BKV-specific T-cells using the combination of multi-parameter
flow cytometry, cell sorting, and NGS-based clonotype profiling.
By means of these comprehensive analyses in a small cohort of
patients with different course and duration of BKV infection,
we identified immunological factors that influence the length
of the clearance time. We found a strong correlation between
the BKV clearance time and TCR repertoire diversity as well as




This study was approved by our local ethical review committee
in compliance with the declaration of Helsinki. Informed and
written consent was obtained from all patients (Ethic Committee
Charité UniversityMedicine, Berlin, Germany, EA2/028/13). The
study cohort consisted of 7 kidney transplant recipients with
sustained BKV reactivation (Table 1). The HLA typing for each
patient and donor is summarized in Figure 1.
BKV Viremia
BKV-DNA copy numbers were determined in serum as
previously described (16). Briefly, DNA was isolated from serum
using a QIAamp DNA Mini Kit (Qiagen) according to the
manufacturer’s instructions. Primers and probes were designed to
amplify the VP1 region of BKV. A plasmid standard containing
the VP1 coding region was used to determine the copy number
per ml. Samples exceeding the detection level (>1,000 copies/ml)
were considered positive.
BKV Stimulation
PBMC were isolated from 40ml freshly drawn heparin-
treated peripheral blood using the Ficoll-Hypaque (PAA
Laboratories) gradient method and collected in RPMI-1640
medium (supplemented with L-glutamine (2 mmol/l), fetal calf
serum (10%), penicillin (100 IU/ml), and streptomycin (0.1
mg/ml), all from Biochrom) and stimulated with overlapping
peptides of all viral products as previously described (17). Briefly,
an overlapping peptide pool was created from individual 15
mer BKV peptides with an 11 amino acids overlap of the
BKV proteins VP1 (Swiss-Prot ID : P14996), VP2 (Swiss-
Prot ID : P03094), VP3 (P Swiss-Prot ID : 03094-2), small T
antigen (Swiss-Prot ID : P03082) and large T antigen (Swiss-
Prot ID : P14999). Although VP3 and small T antigen are
included in the ORF of VP2 and large T antigen, respectively,
both peptides are included in the overlapping peptide pool
to mimic the relative abundance of the epitopes. The scheme
of the 15 mer 11 overlapping peptide pools is illustrated in
Supplementary Figure 1.
All individual peptide pools (JPT) were reconstituted in
DMSO and phosphate-buffered saline (PBS) to 1.5mM (2.5
µg/µl) for each peptide. 0.5–1 × 107 PBMCs were incubated
with the BKV overlapping peptide pool at final concentration
of 1 µg peptide/ml for 16 h at 37◦C, 5% CO2. Brefeldin A
(Sigma-Aldrich) was added at 1µg/ml after 2 h.
Antibodies and Staining Procedure
Cells were stained with anti-CD3-eF650 (Clone: UCHT1;
eBioscience), anti-CD4-PerCP/Cy5.5 (Clone: SK3; BD
Bioscience), anti-CD8-BV570 (Clone: 3B5; Invitrogen), and
Live/Dead NearIR (Invitrogen). The surface staining was
performed in PBS for 15min at room temperature in the dark
and subsequently fixed using Permeabilizing Solution 2 (BD
Biosciences) for 10min at room temperature.
Intracellular staining was performed with anti-CD137-
PE/Cy5 (Clone: 4B4–1; BD Biosciences), anti-CD154-APC/Cy7
(Clone: 24–31; Biolegend), anti-PD1-BV710 (Clone: EH12.2H7;
Biolegend), and anti-TIM3-APC (Clone: F38-2E2; eBioscience)
for 30min at room temperature in the dark.
Samples were acquired on a LSRII-Fortessa (BD Biosciences)
and at least 1.5 × 106 events were recorded. Calibration of
the instrument was reconfirmed weekly with rainbow beads
(BD Biosciences).
TCR Repertoire Analysis
T-cells were sorted by flow cytometry according to CD4 and CD8
expression from unstimulated PBMCs stained with anti-CD3-
eF650 (Clone: UCHT1; eBioscience), anti-CD4-PerCP/Cy5.5
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TABLE 1 | Characteristics of patients with BKV reactivation.
Immunosuppressive medication
Patient Gender Age at Tx (Years) Donor age HLA match BKV viremia onset after Tx Continual* Switch**
1 Male 28 54 3/6 64 days MMF, PRD TAC→ CsA
2 Male 66 2/6 122 days MMF, PRD TAC→ CsA
3 Male 52 3/6 32 days PRD MMF→ AZA;
TAC→ CsA
4 Male 68 77 4/6 94 days MMF, PRD TAC→ CsA
5 Male 59 45 0/6 ∼10.24 years MMF, PRD TAC→ CsA
6 Male 66 0/6 67 days MMF, PRD TAC→ CsA
7 Male 65 39 6/6 ∼6 years MMF, PRD TAC→ CsA
*Therapeutics that remained constant throughout the course of BKV reactivation.
**Alteration of therapeutic regiment upon diagnosis of BKV reactivation. Values in parenthesis indicate the average daily dose.
AZA, azathioprine; CsA, Cyclosporine A; MMF, mycophenolate mofetil; PRD, prednisolone; TAC, tacrolimus.
FIGURE 1 | Recipient and donor HLA type. HLA type of the patients and their kidney donors. Black square indicate presence of the HLA type, white indicate absence.
(Clone: SK3; BD Bioscience), anti-CD8-BV570 (Clone: 3B5;
Invitrogen), and Live/Dead NearIR (Invitrogen) at the BCRT
Flow Cytometry Laboratory. PBMCs were stimulated with the
BKV overlapping peptide pool at final concentration of 1 µg
peptide/ml for 16 h at 37◦C, 5% CO2.in the presence of 1µg/ml
CD40 (Miltenyi Biotec). Activated BKV-specific T-cells were
MACS isolated using the IFNγ Secretion Assay–Cell Enrichment
and Detection Kit, human (Miltenyi Biotec), per manufacturer’s
instructions. Genomic DNA was isolated using the AllPrep
DNA/RNA Micro Kit (Qiagen). The samples were obtained in
follow up after the modification of the immunosuppression.
The recombined V-CDR3-J region of the recombined
genomic TCR-β locus was amplified with partly degenerate
primers covering all functional Vβ and Jβ regions (0.25µM each)
as previously described (18). Using Phusion Hot Start II DNA
Polymerase (Thermo Fisher) and DNA template (up to 1 µg)
in a final volume of up to 100 µl, the PCR reaction was heated
to 98◦C for 5min and followed by typically 20 cycles of 98◦C
15 s, 65◦C 30 s, and 72◦C 30 s, with final extension at 72◦C for
5min. The PCR product was purified with Sera-Mag SpeedBead
Carboxylate-Modified Magnetic Particles (GE Healthcare Life
Sciences) and after washwith 70%EtOh resuspended in nuclease-
free water (Thermo Fisher). Purified PCR product was used in
a second PCR where sample indices were added as above, with
only 14 cycles of PCR. Indexed PCR product was separated on
2%-LMP agarose (Sigma) and purified with the Gel Extraction
Kit (Qiagen).
Sequencing library preparation with consequent sequencing
was performed using Illumina MiSeq Technology at the Next
Generation Sequencing Core Unit at Berlin Brandenburg
Center for Regenerative Therapies, Berlin, Germany. Reads
with an average quality score below 30 were excluded
from further analysis. The remaining high quality reads
were processed using IMSEQ to identify the CDR3 amino
acid sequence (19). CDR3 embedded at wrong reading
frames and with stop codons were discarded. On average
we obtained 488,700 reads per sample, with first and third
quantile of 279,400 and 626,400, respectively. Antigen specific
clonoypes of the unstimulated whole-blood samples were
identified by overlap to clonotypes obtained by the IFNγ
Secretion Assay.
Diversity Estimation
To account for differences in sequence depth, the clonotypes
were rarified to equal sample size before estimation of repertoire
diversity. Rarefaction was performed using the R-package vegan,
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where pi is the proportion of the ith clonotype in the
population (21).





where NA indicates the abundance of the most abundant
clonotype, NT is the total number of clonotypes (22). This index
relies on the most abundant clonotype and is therefore less
sensitive to sequencing errors.
Estimation of Clearance Time
Patients were considered free from BKV viremia if at least two
consecutive measurements were below detection limit. The time
from the highest viral load until complete virus clearance was
estimated from the slope of the linear fit of the log-transformed
measurements spanning from the highest BKV copy number to
the first BKV viremia free measurement. The initial conditions





where BKVmin is the detection limit of 1,000 BKV copies/ml.
Statistical Analysis
Flow cytometry data was analyzed using FlowJo version 10.3
(Tree Star). Statistical analysis was performed using R, version
3.3.1 (23). p-values < 0.05 were considered significant.
RESULTS
BKV Viremia Clearance Time Differs
Between Kidney Transplant Recipients
BKV viremia was monitored in kidney transplant patients with
BKV reactivation (Figure 2). The highest measured BKV copy
number followed by load decline was taken as the start of the
viremia clearance phase. The patient was considered free from
BKV viremia when samples from at least two consecutive time
points were both negative. The first of these time points marked
the end of the viremia clearance phase. The actual clearance is
at a point before the observed clearance. To limit the effect of
sampling frequency, we sought to obtain a data driven length
of the viremia clearance phase by linear regression on log-
transformed BKV viral load. The slope of the fitted curve was
used the slope to estimate the number of days until the virus
was cleared. The linear fit explained 78 to 96% of the variation in
the viremia decline phase (Figure 2A). The estimated clearance
time ranged between 46 and 298 days (Figure 2B). The time with
increasing BKV viremia was similarly estimated through linear
regression (Figure 2C). No association between the length of the
inclining and declining phase was found (data not shown).
Magnitude and Phenotypic Characteristics
of BKV-Specific T-Cells Do Not Explain
Differences in BKV Clearance Time
Previously, we showed that the BK viral load decline was
associated with the reconstitution of helper and cytolytic
BKV-specific T-cells in peripheral blood (6). However, the
factors that affect the BKV infection clearance time were
so far not addressed. Here, we analyzed the effect of
functional and phenotype characteristics on the duration of BKV
clearance (Figure 3A, Supplementary Figures 2–8). First, using
the previously published gating strategy and activation markers
CD137/CD154 for CD4+ T-cells and CD137/Granzyme B for
CD8+ T-cells (6), the frequencies of BKV-specific CD4+ and
CD8+ T-cells circulating in peripheral blood were evaluated. No
correlation between the duration of BKV clearance time and the
ratio of either BKV-specific CD4+ or CD8+ T-cells at the peak
of viral load could be observed (Figures 3B,C). The frequencies
of total CD4+ or CD8+ also did not correlate with the clearance
time (Supplementary Figures 9A,B).
Since previous data demonstrated a better antiviral control
in patients with elevated number of multi-functional cells (17),
we next addressed the question whether functionality of BKV-
specific T-cells could explain the difference in clearance time.
To this end we analyzed multi-functional characteristics of BKV-
specific T-cells as defined by multiple cytokine production (IL2,
TNFα, and IFNγ) and/or effector molecule Granzyme B. The
analysis of BKV-specific cytokine multifunctional and effector
molecule producing capacities did not reveal any influence on
duration of clearance period (Supplementary Figures 9C,D).
Tracking of BKV-Specific TCRs
Previous studies on the protective function of cellular immunity
in cancer suggest an important role of the TCR repertoire (24,
25). However, in case of viral infections it is not clear, whether
few immunodominant clones or rather diverse, polyclonal TCR
repertoires determine the clinical course infection (26, 27).
Addressing this question, we analyzed BKV-specific T-cells on a
single clone level during BKV clearance.
We have previously used NGS-based clonotype profiling to
identify BKV-specific T-cell clones and track them in peripheral
blood, renal tissue biopsy, and urine (18). Using a similar
approach, we were able to study the kinetics of BKV-specific T-
cells on the clonal level of whole blood-derived CD4+ and CD8+
T-cell subsets in the current study (Figure 4). Antigen specific
clonoypes of the whole-blood derived samples were identified
by identity to BKV-specific clonotypes obtained by the IFNγ
Secretion Assay. The distribution of length TCRβ CDR3 of these
BKV-specific clonotypes had a similar shape for all patients and
was normally distributed in all cases (Supplementary Figure 10).
A tendency for slightly longer CDR3 was observed for patient
3 (17 AA on average compared to 15 AA for the others;
Supplementary Table 1). However, the most abundant length for
the patients was 15 AA.
The TCRβ V-segment V6 dominated the BKV-specific
clonotypes in all patients. The segment V7 was also dominant
in the patients 1 and 7 (Supplementary Figure 11A). The
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FIGURE 2 | Difference in BKV viremia clearance time. (A) BKV viremia remission phase for the individual patients in the cohort. The dotted line indicates the best linear
fit from the time point before BKV-reactivation to highest BKV load and from the highest BKV load to the first time point with BKV viremia below detection limit. R2
indicate the goodness of fit for the time of increasing BKV viremia and for the time with decreasing viremia. (B) Association of time of increasing BKV viremia and the
time to clear the virus. (C) Clearance time calculated from the slope of a straight line from the highest BKV value to the first time point with BKV viremia below
detection limit.
J-segment J2-1 was found to be frequent in all patients,
but also J1-1 and for patient 5 the J1-6 were also present
(Supplementary Figure 11B). When comparing the V-J-
segment usage, combinations of the most dominant V- and
J-segments for each patient were frequently found, but otherwise
no particular pattern was visible (Supplementary Figure 11C).
In our study we identified BKV-specific T-cell clonotypes and
followed them in peripheral blood of renal transplant patients at
the time point of initiation of viral decline and after the resolution
of BKV infection.While tracking BKV-specific clonotypes during
the course of viral decline we observed substantial changes in
TCR repertoires. While only 0.9% (range: 0–22.0%) of clonotypes
remained stable during the clinical course of BKV clearance,
28.4% (range: 0.4–87.5%) of clonotypes showed expansion and
64.2% (range: 4.9–98.8%) of clonotypes showed loss in their
frequencies (Figure 4A). We also analyzed changes in TCR
repertoire between mid-time of viral decline and after BKV
clearance (Figure 4B). Similarly strong repertoire changes were
observed in most patients in the course of viral load decline
(mid-time–resolution). With respect to the role of repertoire
turn-over for the viral clearance, no specific patterns could be
clearly detected. However, in patient 7, with severe long-lasting
BKV replication, we observed a high number of stably detectable
clonotypes (40% of BKV-specific clones). This case was especially
pronounced between mid-time and viral clearance as compared
to other patients (Figure 4B).
Low Diversity of BKV-Specific Clonotypes
Indicates Prolonged Clearance Time
We next asked how the TCR repertoire diversity of BKV-
specific T-cells reflected the differences in clearance time. We
first evaluated the commonly used Shannon index, but found
no pattern associating with the clearance time (Figure 5A).
Berger-Parker is another diversity index, which disregards the
clonotypes with very low frequency (that is the tail of the
distribution), and can therefore be considered a more robust
index (28). When we looked at inverse of the Berger-Parker
index—which directly reflects the clonal diversity of an analyzed
population—we found a strong correlation to the clearance time
(Figure 5B, Supplementary Figure 12D; Pearson correlation:
−0.99, p-value: 0.013).
We also assessed the clonal size of the TCR repertoire
and cumulative frequencies of BKV-specific TCR by
analyses of most abundant BKV-specific T-cell clones
(Supplementary Figure 12E). Clonal size data were in line
with the data on repertoire diversity. Thus, in cases of low
diversity, cumulative frequencies of the most abundant
clonotypes were much higher and accounted for a lower
diversity than in cases where cumulative frequencies of most
abundant clonotypes were low. In detail, the lowest repertoire
diversity corresponded to 25.1 % as a cumulative frequency
of 10 most abundant clones, whereas the highest repertoire
diversity corresponded to a cumulative frequency of 2.0% for
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FIGURE 3 | Clearance time is not explained by magnitude and phenotypic characteristics of BKV-specific T-cells. (A) Gating strategy applied in the current study.
(B,C) Pearson correlation of clearance time with BKV-specific CD4+ T-cells (B) and BKV-specific CD8+ T-cells (C). Each point represents a patient in the study and
the dotted line the best linear fit.
the 10 most abundant clones. Accordingly to the diversity index
analyses, low cumulative levels correlated with short clearance
time (Pearson: 0.99, p-value: 0.01). The observed correlations
were not due to general differences in complete CD4+ T-cell
repertoire (Supplementary Figures 12A–C).
Activation Can Counteract Low Diversity
Patient 3 clearly rejected the observed pattern. This particular
patient showed a fast BKV load decline but a very low
level of BKV-specific TCR repertoire diversity (Figure 5B). We
therefore asked whether the expansion of few BKV-specific
clones could explain this aberrant behavior. We reasoned that
any expansion in vivo would be reflected in expanded levels of
antigen specific T-cells and performed, consequently, in-depth
characterization of BKV-specific T-cell immunity in this patient
by flow cytometry. Of interest, we detected very high frequencies
of BKV-specific CD4+ and CD8+ T-cells in peripheral blood
of patient 3; the magnitude of the T-cell response was almost
10 times higher compared to the frequencies among the other
patients (Figure 5C).
Prolonged Clearance Time Correlates With
Expression of Exhaustion Markers
In addition to the demonstrated correlation between repertoire
diversity and clearance time, we also evaluated the role of
functional exhaustion of BKV-specific T-cells. Flow cytometric
analysis of the exhaustion markers PD1 and TIM3 on
CD4+ T-cells demonstrated a very strong correlation between
the expression of these markers on BKV-specific CD4+
T-cells and the clearance time (Figure 5D). Interestingly
no association to co-expression of PD1 and TIM3 was
observed (Supplementary Figure 13C). No expression of either
exhaustion marker was seen among BKV-specific CD8+ T-
cells (Supplementary Figures 13A,B). Our data thus show that
exhaustion of the CD4+ T-cells is associated with extended
clearance time.
DISCUSSION
The present study provides characterization of BKV-specific T-
cells in a small cohort of renal transplant recipients. In line with
previous reports (7, 8), we observed significant differences in
clearance time of BKV virus. We used modern high throughput
technologies such as next generation sequencing and multi-
parameter flow cytometric analysis to address the question how
the fitness of the immune system affects the BKV clearance
time. Here, we presented evidence that the diversity of the BKV-
specific TCR repertoire inversely correlates with the duration
of BKV clearance from initiation of the load decline until
virus clearance. In addition, we showed that the expression of
exhaustion markers PD1 and TIM3 on BKV-specific CD4+ T-
cells at the time point of initial BKV load decline correlates with
sustained BKV reactivation, while lack of the PD1 and TIM3
expression corresponded to shorter clearance time. These data
therefore suggest that the repertoire diversity and functional
fitness of BKV-specific T-cells as defined by the expression of
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FIGURE 4 | Tracking of BKV-specific TCR clonotypes. BKV-specific TCR clonotypes were obtained from IFNγ producing T-cells after stimulation with BKV overlapping
peptide pools. TCR clonotypes from whole blood CD4+ and CD8+ subsets were obtained at different stages of viral clearance. The overlap between the clonotypes
of whole blood samples and clonotypes of the IFNγ producing T-cells were identified as BKV-specific T-cells in circulation. The abundance of these circulating
BKV-specific T-cells were subsequently compared at distinct stages of viral clearance. Black bars indicate the frequency of clonotypes gained from the earlier to the
later time point. Dark gray indicates the frequency of clonotypes found at both time points. Light gray indicates the frequency of clonotypes that has disappeared from
the earlier time point to the later. (A) Relative change in BKV-specific clonotypes from the initiation of viral clearance (before) to the resolution of BKV infection (after).
(B) Relative change in BKV-specific clonotypes from T-cells obtained during the clearance phase (mid) to the resolution of BKV infection (after). The bars indicate the
frequency of clonotypes gained, lost, or sustained as the viral clearance progressed, that is, clonotypes that were present after viral clearance, but not before;
clonotypes that were present at the beginning of the clearance phase but not after; and clonotypes present before and after viral clearance.
exhaustion markers are key players in determining the clinical
course of viral infection and clearance.
The essential role of T-cells in controlling BKV reactivation
and clearance is well-established. We have previously shown
that the loss of BKV-specific T-cells is associated with a higher
risk of BK viremia (29) and that an increase in BKV-specific T-
cell response corresponded to the clearance of BKV reactivation
(4). The current recommendation for the management of
BKV infection in renal transplant patients includes accordingly
a reduction or modification of immunosuppressive therapy
allowing for an immune system reconstitution. In fact,
frequencies of BKV-specific T-cells increase upon reduction
of immunosuppression as demonstrated previously (5, 30).
However, despite similar therapeutic approaches, the duration
of BKV clearance varies among patients spanning period of
time from several weeks to even years (7, 8). Factors that
might be responsible for the different clinical course of BKV
infection are not identified so far. Addressing the role of the
magnitude of BKV-specific T-cell immunity we analyzed the
frequencies of BKV-specific T-cells in a small patient cohort. No
correlation was found between the duration of viral clearance
and the frequencies of BKV-specific T-cells. We also analyzed the
role of the functional characteristics of BKV-specific T-cells on
the clinical course of infection. Previous studies demonstrated
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FIGURE 5 | Repertoire analysis of BKV-specific T-cells. BKV-specific T-cells were isolated and subjected to clonotype analysis. (A) Population diversity by the
Shannon index and the inverse Berger-Parker index (B). (C) Comparison of total BKV-specific CD4+ T-cells (left panel) and CD8+ T-cells (right panel), for patient 2
and the other patients. (D) Pearson correlation of clearance time and cellular exhaustion as marked by PD1 and TIM3 among activated CD4+ T-cells, see
Supplementary Figures 2–8 for details. Presented is the ratio of stimulated to negative control (DMSO treated). Each point represents a patient in the study and the
dotted line the best linear fit.
an important role of multi-functional T-cells for the control
of chronic infections (31–33). Our own data in patients with
a history of resolved low-level BKV infection demonstrated a
higher number of multi-functional CD4+ T-cells compared to
patients with a history of severe long-lasting BKV infection (17).
Our present finding that the frequencies of BKV-specific multi-
functional T-cells at the peak of viral load did not associate with
a shorter clearance time, indicate the importance of other factors
once the viral control is broken.
Assessment of T-cell receptor repertoires and T-cell clonality
is the focus of many immunological studies providing in-depth
T-cell characterization (24, 34–36). This technology provides a
unique potential for the analysis of memory T-cells in humans,
e.g., clonal relations between circulating and resident cells or
various functional subsets (34, 37); assessment of T-cell repertoire
size and diversity (10); detection and tracking of antigen-
specific T-cells within various tissue samples (14, 18). In some
clinical situations, TCR repertoire profiling is the only available
method to differentiate between an undesired pathological T-cell
response and a local protective antiviral immune response, i.e.,
the case of acute transplant rejection by alloreactive T-cells vs.
BKV clearance by virus-specific T-cells infiltrating the kidney
transplant (18, 38). Questions regarding the role of clonotype
diversity and protective capacity of the adaptive cellular immune
response remain so far not completely resolved. Some studies
suggest that diversity and size of the antigen-specific TCR
repertoire are two critical determinants for successful control
of chronic infections and that the decreased repertoire diversity
in age correlates with the decline of immune responsiveness
in aging (10).
Although it is generally believed that a large T-cell clonotype
diversity provides the optimal protection (27, 39), mice with
reduced TCR diversity are capable of controlling LCMV or
Sendai virus infections (40) and differences in diversity of
influenza-specific CD8+ T-cells were not reflected in differences
in overall functionality (41). On the other hand, an association
between TCRβ chain high diversity and low incidence of CMV
and EBV reactivations has been observed in solid organ or
hematopoietic stem cell transplant patients such that higher
diversity yields lower incidence (42–44).
In line with these data, we here demonstrated a negative
correlation between diversity level and clearance time of
BKV infection. However, a single patient defied the observed
association.We believe that the low diversity level was substituted
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by a high level of functional fitness of BKV-specific T-cells. In fact,
we observed a nearly 10 times higher frequency of BKV-specific
T-cells in the analyzed as compared to the other patients and very
low levels of PD1 or TIM3 expression on BKV-specific CD4+ T-
cells at the peak of BKV viral load. The large frequency and low
diversity was reflected in a strong dominance of the first 10 most
abundant BKV-specific clonotypes which indicates an expansion
of particular T-cell clones. The relationship between the strength
of the TCR signal and the proliferation of the T-cell is well-
established (45). It is therefore possible that highly specific T-cell
clones dominate in this one patient, resulting in low diversity of
the overall BKV-specific repertoire. In a more general sense, it
might be that most BKV-specific TCRs are of lower avidity and
that high avidity TCRs are rare and generated by chance. This
also explains the observation, where low diversity leads to longer
clearance times: a broader TCR repertoire is better equipped to
generate a population of BKV-specific T-cells required to initiate
and maintain the clearance of the virus (4, 5). We are currently
in the process of elucidating the avidity of a select number of the
identified BKV specific clonotypes.
An alternative explanation to the low diversity but fast
clearance of patient 3 could be that the patient has a particular
set of HLA molecules, which allow strong presentation of
immunogenic BKV epitopes. However, the haplotypes of patient
3 were the same as for patient 4; at least on the level of allele
group. This indicates that the HLA haplotype alone is insufficient
to explain the TCR diversity.
The expression of the exhaustion markers PD1 and TIM3
on the CD4+ T-cells displayed in both cases a straight forward
relationship with the clearance time, such that the absence
of exhaustion markers was associated with shorter clearance
time. This makes it possible, that the fitness of the T-cells
is a major player in creating a pool of BKV controlling T-
cells in addition to the repertoire diversity. Since both the
repertoire diversity and the expression of exhaustion markers
correlated with the clearance rate, it is possible that one effect
depends on another one: low diversity leads to insufficient
clearance and therefore to long-lasting BKV reactivation with
a subsequent sustained activation of BKV-specific T-cells. This
long-lasting T-cell activation could result in a high-level of
exhaustion. Alternatively, the expression of exhaustion makers
leading to a functional impairment of T-cells might lead to
a protracted viral elimination and contribute therefore to a
permanent activation of BKV. Such permanent antigenic stimuli
can lead to clonal skewing with an expansion of a few clones,
similar to a phenomenon described for older patients with
CMV reactivations (46). Although our study provided first
observations between T-cell functionality, duration of viral
clearance, and T-cell clonality; the interplay between the T-cell
exhaustion status and the TCR repertoire diversity is of special
interest and will be addressed in ongoing studies.
Our study is limited in that it is based on a small cohort of
7 kidney transplant patients, with TCRβ CDR3 data available
for only 5 of these 7 patients. This is arguably a very small
cohort. However, the observed associations had high correlation
coefficients indicating small variance in the data, and thus
indicating that the findings presented here are robust, despite
the small cohort. The associated p-values were likewise small,
confirming that the observations might not be per chance
only. The viral load can fluctuate by up to one log, but we
generally observed a steady decline in BKV copies/ml after
some maximal value. We therefore defined the start of the
clearance phase as the peak in BKV viremia. Other definitions
might be valid, but they would affect the clearance duration
for all patients equally, and thereby not disturb the order of
clearance times.
Though the results presented here are sturdy, the small
cohort warrants caution. The reason for the low cohort size
is due to the low number or kidney transplant patients where
decrease of the immuno suppressive regime is insufficient for
FIGURE 6 | Summary of hypothesis. Low exhaustion and high TCRβ diversity results in shorter clearance time (black line), while high exhaustion and low TCRβ
diversity results in shorter clearance time (gray line).
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rapid clearance of the BK-virus. The second reason relates to
the problem of timing; the course of the viral reactivation is
inherently unpredictive, which make the acquisition of samples
at the peak of reactivation very much a case of hit and miss.
Future studies addressing the role of TCR diversity and T-cell
exhaustion in general, and for BKV in particular, should isolate
and store PBMCs at regular intervals. Ideally the regular screen
encompasses all transplant patients in order to systematically
attain samples before and at the time of reactivation. For
patients with reactivation the screen should include a long-
term follow-up after clearance, irrespective of the efficacy of the
immune modulation.
In summary, we propose that the exhaustion status of CD4+
T-cells affects the diversity of the antigen specific TCR repertoire
resulting in prolonged clearance time after BKV reactivation
(Figure 6). It will be interesting to see if this is a particular feature
of the control of BKV in a transplantation setting, or if this is
general to chronic infections.
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